1. Home
  2. TRIN vs NVAX Comparison

TRIN vs NVAX Comparison

Compare TRIN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trinity Capital Inc.

TRIN

Trinity Capital Inc.

HOLD

Current Price

$16.51

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.95

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIN
NVAX
Founded
2007
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
TRIN
NVAX
Price
$16.51
$9.95
Analyst Decision
Buy
Hold
Analyst Count
5
9
Target Price
$16.00
$10.78
AVG Volume (30 Days)
1.3M
4.6M
Earning Date
02-25-2026
02-26-2026
Dividend Yield
12.67%
N/A
EPS Growth
25.79
N/A
EPS
2.17
2.07
Revenue
$268,271,000.00
$1,064,651,000.00
Revenue This Year
$31.25
$58.91
Revenue Next Year
$16.06
N/A
P/E Ratio
$7.43
$3.96
Revenue Growth
30.76
20.27
52 Week Low
$12.50
$5.01
52 Week High
$16.82
$10.65

Technical Indicators

Market Signals
Indicator
TRIN
NVAX
Relative Strength Index (RSI) 70.03 76.49
Support Level $15.89 $7.73
Resistance Level $16.34 $8.81
Average True Range (ATR) 0.36 0.56
MACD 0.09 0.21
Stochastic Oscillator 99.26 99.41

Price Performance

Historical Comparison
TRIN
NVAX

About TRIN Trinity Capital Inc.

Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: